REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place in New Orleans, May 13 through 17, 2025. The presentations highlight REGENXBIO’s leading end-to-end capabilities across research and early development, late-stage clinical development, and gene therapy manufacturing.
Presentations include encore data from late-stage clinical trials of RGX-121 (clemidsogene lanparvovec) for the treatment of MPS II and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as preclinical research supporting the novel construct of RGX-202 with the C-Terminal domain, capsid discovery research, and RGX-202 manufacturing process development enabling industry-leading purity levels in Duchenne gene therapy.
